bioAffinity Technologies, Inc. (BIAF) - Long-Term Debt to Capital

This daily price action for bioAffinity Technologies (BIAF) reflects metrics where the long-term debt-to-equity ratio stands at 0.30. bioAffinity Technologies is implementing ESG environmental standards into molecular screening, minimizing emissions and digitizing reporting. Sample preparation automation via CyPath Lung AI systems accelerates pathology detection. Business stability is based on a unique sputum analysis method integrated into US oncology screening protocols.

Developing AI algorithms for lung cancer diagnostics requires significant capital expenditures in automation. The long-term debt-to-equity ratio reflects the financing strategy for these technological processes. This metric compares credit obligations exceeding one year with net assets, revealing the extent to which development depends on external loans. Minimal index values confirm financial autonomy but may indicate management conservatism. A stable balance confirms the resilience of the capital structure of bioAffinity Technologies (BIAF).